ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ALZN Alzamend Neuro Inc

0.594399
0.00 (0.00%)
Pre Market
Last Updated: 04:00:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 0.50
Ask Price 0.652
News -
Day High

Low
0.4388

52 Week Range

High
11.91

Day Low
Company Name Stock Ticker Symbol Market Type
Alzamend Neuro Inc ALZN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 0.594399 04:00:00
Open Price Low Price High Price Close Price Prev Close
0.594399
Trades Volume Avg Volume 52 Week Range
0 0 - 0.4388 - 11.91
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.594399 USD

Alzamend Neuro Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
4.2M 7.12M - 0 -14.88M -2.09 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Alzamend Neuro News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ALZN Message Board. Create One! See More Posts on ALZN Message Board See More Message Board Posts

Historical ALZN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.6450.680.5650.61403945,500-0.0506-7.85%
1 Month0.740.780.43880.5942453107,992-0.1456-19.68%
3 Months0.941.290.43880.835564786,856-0.3456-36.77%
6 Months1.111.290.43880.895088869,108-0.5156-46.45%
1 Year8.1011.910.43883.81150,162-7.51-92.66%
3 Years435.00503.250.438841.891,191,340-434.41-99.86%
5 Years435.00503.250.438841.891,191,340-434.41-99.86%

Alzamend Neuro Description

Alzamend Neuro Inc is an early clinical stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Your Recent History

Delayed Upgrade Clock